Neurosense Therapeutics Ltd (NRSN) Stock Price, Quote & News

Company Profile

NeuroSense Therapeutics Ltd., a clinical-stage biotechnology company, focuses on discovering and developing treatments for patients suffering from neurodegenerative diseases in the United States and internationally. The company's lead product is PrimeC, an extended-release oral formulation of a fixed-dose combination of ciprofloxacin and celecoxib, currently under Phase 2b/3 clinical trials for the treatment of amyotrophic lateral sclerosis, and completed Phase 2 clinical trials for the treatmen...

Industry: Biotechnology

Sector: Healthcare

Phone: 972 9 799 6183

Website: www.neurosense-tx.com

Address:

Building B, 11 HaMenofim Street, Herzliya, Israel

lev57 Aug. 19 at 5:27 PM

$NRSN No one will intimidate and break us. Together we will return the value to the society that is worth it. We cannot be broken as a group.

0 · Reply

lev57 Aug. 19 at 5:23 PM

$NRSN All the prophets of wrath are repeating "We told you so" Maybe they are part of the problem for the fall? Together we will restore the value to the society that is worth it.

0 · Reply

lev57 Aug. 19 at 5:20 PM

$NRSN This turnover is not just high. A lot of goods were bought cheaply. Together we will return the value to the company that made it worth it.

0 · Reply

tiddyy Aug. 19 at 5:20 PM

$NRSN To all the people. I told you. GGs

0 · Reply

lev57 Aug. 19 at 5:04 PM

$NRSN alon keep me updated. I operate in multiple channels to bring value to investors. Official updates in due course. Don't be tempted and sell cheap. Buy cheap and sell high.

0 · Reply

lev57 Aug. 19 at 4:45 PM

$NRSN I wonder who did it. Maybe the one who warned me? The short-termists came and broke up the company. Together we will prevent it from them.

0 · Reply

IntentionalTrades Aug. 19 at 4:29 PM

$NRSN I warned the would be investors, hopefully nobody lost money.

0 · Reply

lev57 Aug. 19 at 4:27 PM

$NRSN The short-termists came to dismantle the company. Together we will prevent this from them.

0 · Reply

lev57 Aug. 19 at 3:52 PM

$NRSN Something is brewing that hasn't been announced yet. It's worth waiting. Don't sell cheap. You'll regret it.

0 · Reply

Stekli27 Aug. 19 at 3:48 PM

$NRSN why such a volume????

0 · Reply

NeuroSense Issues CEO Letter to Shareholders

2026-08-06T15:35:50.000Z - 13 days ago

NeuroSense sees December 2026 as filing date for NDS for PrimeC

Aug 6, 2026, 11:29 AM EDT - 13 days ago

NeuroSense Completes PrimeC Pre-NDS Process and Advances Toward December 2026 Filing with Health Canada

Jul 30, 2026, 8:00 AM EDT - 20 days ago

NeuroSense Therapeutics Registration statement: Registration filing

Jul 28, 2026, 8:00 AM EDT - 22 days ago

NeuroSense Therapeutics Slides: Corporate presentation

2026-07-22T12:35:29.000Z - 4 weeks ago

NeuroSense to file NDS to Health Canada for PrimeC for treatment of ALS

Jul 22, 2026, 8:30 AM EDT - 4 weeks ago

NeuroSense Advances PrimeC Toward New Drug Submission to Health Canada for ALS

Jul 6, 2026, 8:45 AM EDT - 6 weeks ago

NeuroSense to Participate in Roth-Hosted KOL Webinar on the Future of ALS Treatment: "A Quest to Outrun ALS"

2026-06-29T13:35:17.000Z - 7 weeks ago

NeuroSense says Phase 2b PARADIGM study of PrimeC in ALS met endpoint

Jun 29, 2026, 9:30 AM EDT - 7 weeks ago

NeuroSense Achieves Primary Endpoint in Phase 2b ALS Study with Statistically Significant Reduction of TDP-43, the Defining Pathological Hallmark of ALS

Jun 25, 2026, 9:20 AM EDT - 7 weeks ago

NeuroSense Reports Positive Biomarker Findings from Phase 2 RoAD Proof-of-Concept Study of PrimeC in Alzheimer's Disease

Jun 22, 2026, 9:00 AM EDT - 2 months ago

EverythingALS to Host NeuroSense in a Community Event Named: PrimeC - Connecting the Dots

2026-06-11T13:09:31.000Z - 2 months ago

NeuroSense granted South Korean patent covering PrimeC composition for ALS

Jun 11, 2026, 9:00 AM EDT - 2 months ago

NeuroSense Granted South Korean Patent Covering PrimeC Composition for ALS

2026-06-09T13:19:06.000Z - 2 months ago

NeuroSense granted Japanese patent for PrimeC novel composition in ALS

Jun 9, 2026, 9:00 AM EDT - 2 months ago

NeuroSense Therapeutics Receives Japanese Patent Grant for PrimeC Novel Composition

May 4, 2026, 7:00 AM EDT - 3 months ago

NeuroSense Therapeutics Slides: Corporate presentation

Apr 28, 2026, 2:30 PM EDT - 4 months ago

NeuroSense Announces Pricing of Insider-Led PIPE Financing

2026-04-26T22:31:45.000Z - 4 months ago

NeuroSense announces departure of Chief Medical Officer

Apr 14, 2026, 7:00 AM EDT - 4 months ago

NeuroSense Therapeutics Slides: Corporate presentation

2026-04-06T13:34:33.000Z - 4 months ago

NeuroSense granted Brazilian patent covering PrimeC composition

Apr 6, 2026, 9:20 AM EDT - 4 months ago

NeuroSense Granted Brazilian Patent Covering PrimeC Composition

Apr 3, 2026, 10:02 AM EDT - 4 months ago

NeuroSense Therapeutics Announces Receipt of Nasdaq Notifications Regarding Minimum Bid Price and Market Value Requirements

Mar 31, 2026, 9:30 AM EDT - 5 months ago

NeuroSense Therapeutics Annual report: Q4 2025

Mar 31, 2026, 9:30 AM EDT - 5 months ago

NeuroSense Therapeutics Earnings release: Q4 2025

Mar 31, 2026, 9:20 AM EDT - 5 months ago

NeuroSense Therapeutics Reports Year End 2025 Financial Results and Provides Business Update

Mar 24, 2026, 9:00 AM EDT - 5 months ago

NeuroSense Advances Toward Key Regulatory Milestones with Strengthened Data Package and Near-Term Alzheimer's Readout

Mar 18, 2026, 8:00 AM EDT - 5 months ago

PrimeC New Data to Be Presented at AD/PD™ 2026 Conference

Mar 16, 2026, 11:33 AM EDT - 5 months ago

JAMA Neurology Publishes Results from PARADIGM Phase 2b Trial of PrimeC in ALS Demonstrating Meaningful Clinical Outcomes and Biological Activity

Mar 11, 2026, 7:00 AM EDT - 5 months ago

NeuroSense Therapeutics Slides: Corporate presentation

2026-03-10T08:30:39.000Z - 5 months ago

NeuroSense initiated with a Buy at Roth Capital

Mar 9, 2026, 11:07 AM EDT - 5 months ago

PrimeC Long-Term Survival Data to Be Presented at a Leading ALS Scientific Conference

2026-02-18T14:10:54.000Z - 6 months ago

NeuroSense reports additional long-term survival data from PARADIGM 2b trial

Feb 18, 2026, 9:05 AM EST - 6 months ago

NeuroSense Announces Statistically Significant 65% Reduction in Risk of Death and Greater than 14-Month Median Survival Benefit with PrimeC in ALS

2026-02-09T14:25:44.000Z - 6 months ago

NeuroSense granted Australian patent covering PrimeC composition

Feb 9, 2026, 9:20 AM EST - 6 months ago

NeuroSense Expands Global IP Protection Strategy With Granted Australian Patent Covering PrimeC Composition

2026-01-29T22:30:20.000Z - 7 months ago

NeuroSense files $150M mixed securities shelf

Jan 29, 2026, 7:00 AM EST - 7 months ago

NeuroSense Therapeutics Registration statement: Registration Filing

Jan 21, 2026, 8:30 AM EST - 7 months ago

NeuroSense Granted U.S. Patent for Treatment of Alzheimer's Disease

Jan 8, 2026, 8:45 AM EST - 7 months ago

World-Renowned Alzheimer's Expert Prof. Steven Arnold Joins NeuroSense SAB

Jan 4, 2026, 7:00 AM EST - 8 months ago

NeuroSense Therapeutics Slides: Corporate presentation

2025-12-22T14:25:57.000Z - 8 months ago

NeuroSense confirms favorable safety, tolerability of Prime C in Phase 2 study

Dec 22, 2025, 9:17 AM EST - 8 months ago

NeuroSense Confirms Favorable Safety and Tolerability of PrimeC in an Alzheimer's Phase 2 Study

Dec 9, 2025, 7:00 AM EST - 9 months ago

NeuroSense Therapeutics Slides: Corporate Presentation

Dec 8, 2025, 8:30 AM EST - 9 months ago

NeuroSense Therapeutics Transcript: Status Update

Dec 4, 2025, 7:30 AM EST - 9 months ago

NeuroSense to Hold Pre-NDS Meeting with Health Canada in April 2026

2025-11-24T15:05:50.000Z - 9 months ago

NeuroSense reports FDA clearance to initiate Phase 3 trial for PrimeC in ALS

Nov 24, 2025, 9:56 AM EST - 9 months ago

NeuroSense Receives FDA Clearance to Initiate Pivotal Phase 3 Trial for PrimeC in ALS

Nov 3, 2025, 9:15 AM EST - 10 months ago

NeuroSense to Host Investor Webinar on December 8, 2025

2025-10-28T20:36:43.000Z - 10 months ago

NeuroSense files to sell 333K ordinary shares for holders

Oct 28, 2025, 8:00 AM EDT - 10 months ago

NeuroSense Therapeutics Registration statement: Registration Filing

2025-10-14T13:35:14.000Z - 11 months ago

NeuroSense initiated with an Outperform at Noble Capital

2025-10-06T13:10:33.000Z - 11 months ago

NeuroSense announces ‘positive’ results from Phase-2b PARADIGM study

Oct 6, 2025, 9:00 AM EDT - 11 months ago

NeuroSense: PrimeC Produces Statistically Significant Reductions in Alzheimer's Disease Biomarkers

Sep 10, 2025, 2:30 PM EDT - 1 year ago

NeuroSense's Drug Candidate Shows Early Signals of Benefit in Alzheimer's Patient-Derived Neurons

Sep 4, 2025, 8:49 AM EDT - 1 year ago

NeuroSense Therapeutics Announces $500,000 Private Placement at Premium to Market Price

2025-08-20T13:50:08.000Z - 1 year ago

NeuroSense reports 20% of people with ALS from Phase 2a study remain on PrimeC

Aug 1, 2025, 9:00 AM EDT - 1 year ago

NeuroSense Provides Business Update and Progress for the First Half of 2025

Jul 31, 2025, 6:00 PM EDT - 1 year ago

NeuroSense Therapeutics Earnings release: Q2 2025

Jul 22, 2025, 8:42 AM EDT - 1 year ago

Award-Winning Broadway, Television & Film Star Aaron Lazar Featuring NeuroSense CEO Alon Ben-Noon in a Special Live Podcast on ALS Science, PrimeC's Commercialization Strategies, and Community

2025-05-12T11:30:59.000Z - 1 year ago

NeuroSense initiated with a Buy at D. Boral Capital

May 7, 2025, 8:45 AM EDT - 1 year ago

NeuroSense Therapeutics Announces Successful Completion of Commercial Manufacturing Scale-Up for PrimeC in Preparation for Potential Canadian Market Launch

Apr 24, 2025, 9:09 AM EDT - 1 year ago

NeuroSense Therapeutics Releases Letter to Shareholders Outlining Clinical Progress, Regulatory Strategy, and Partnership Update

Apr 9, 2025, 8:30 AM EDT - 1 year ago

NeuroSense Therapeutics Announces Transformative Phase 2b MicroRNA Data, Highlighting PrimeC's Promise as a Disease-Modifying ALS Treatment

Apr 7, 2025, 5:14 PM EDT - 1 year ago

NeuroSense Therapeutics Reports Year End 2024 Financial Results and Provides Business Updates

Apr 7, 2025, 4:00 PM EDT - 1 year ago

NeuroSense Therapeutics Earnings release: Q4 2024

Apr 7, 2025, 4:00 PM EDT - 1 year ago

NeuroSense Therapeutics Annual report: Q4 2024

Apr 4, 2025, 9:10 AM EDT - 1 year ago

NeuroSense Therapeutics to Present New Data from PrimeC's Phase 2b Trial in ALS at the Annual American Academy of Neurology Meeting

Mar 17, 2025, 8:30 AM EDT - 1 year ago

PESG Releases Report on NeuroSense Therapeutics: Groundbreaking ALS Therapy Signals Massive Potential Opportunity in Billion Dollar Treatment Landscape

2025-01-06T14:11:26.000Z - 1 year ago

NeuroSense regains Nasdaq compliance

Jan 6, 2025, 9:00 AM EST - 1 year ago

NeuroSense Regains Compliance with Nasdaq's Minimum Equity Requirement

Dec 26, 2024, 7:00 AM EST - 1 year ago

NeuroSense Therapeutics Registration statement: Registration Filing

Dec 23, 2024, 9:00 AM EST - 1 year ago

NeuroSense Therapeutics Enters Binding Term Sheet to Advance PrimeC for ALS

Dec 18, 2024, 10:25 AM EST - 1 year ago

NeuroSense Provides Business Update and Third Quarter 2024 Financial Results

Dec 18, 2024, 8:00 AM EST - 1 year ago

NeuroSense Therapeutics Earnings release: Q3 2024

Dec 11, 2024, 9:25 AM EST - 1 year ago

NeuroSense Receives Positive FDA Feedback on Phase 3 Study Design for PrimeC

Dec 6, 2024, 7:00 AM EST - 1 year ago

NeuroSense Therapeutics Registration statement: Registration Filing

Dec 4, 2024, 8:30 AM EST - 1 year ago

NeuroSense Announces Completion of PARADIGM Study Highlighting PrimeC's Significant Efficacy and Survival Benefits in ALS

Dec 2, 2024, 8:30 AM EST - 1 year ago

NeuroSense Therapeutics Announces $5 Million Private Placement at Premium to Market Price

Nov 21, 2024, 9:20 AM EST - 1 year ago

NeuroSense Therapeutics to Participate in the 2024 International Symposium on ALS/MND

Nov 19, 2024, 7:00 AM EST - 1 year ago

NeuroSense Therapeutics Registration statement: Registration Filing

Oct 28, 2024, 8:30 AM EDT - 1 year ago

NeuroSense Secures Key FDA Meeting to Advance its Phase 3 ALS Trial and NDA Submission

Oct 24, 2024, 8:30 AM EDT - 1 year ago

New Analysis Shows PrimeC Significantly Improves Key miRNAs in ALS Patients

Oct 15, 2024, 9:15 AM EDT - 2 years ago

NeuroSense Advances Plans for Early Commercialization of Groundbreaking ALS Treatment in Canada, Provides Further Updates

Oct 9, 2024, 9:00 AM EDT - 2 years ago

NeuroSense Therapeutics Plans to File for Early Commercialization of ALS Treatment in Canada

Oct 7, 2024, 9:00 AM EDT - 2 years ago

NeuroSense Therapeutics Announces Acceptance of Two PrimeC Abstracts at the 2024 NEALS Annual Meeting

Sep 24, 2024, 9:05 AM EDT - 2 years ago

NeuroSense Therapeutics Granted Key U.S. Patent for Novel PrimeC Formulation, its Lead Asset for ALS and Alzheimer's

lev57 Aug. 19 at 5:27 PM

$NRSN No one will intimidate and break us. Together we will return the value to the society that is worth it. We cannot be broken as a group.

0 · Reply

lev57 Aug. 19 at 5:23 PM

$NRSN All the prophets of wrath are repeating "We told you so" Maybe they are part of the problem for the fall? Together we will restore the value to the society that is worth it.

0 · Reply

lev57 Aug. 19 at 5:20 PM

$NRSN This turnover is not just high. A lot of goods were bought cheaply. Together we will return the value to the company that made it worth it.

0 · Reply

tiddyy Aug. 19 at 5:20 PM

$NRSN To all the people. I told you. GGs

0 · Reply

lev57 Aug. 19 at 5:04 PM

$NRSN alon keep me updated. I operate in multiple channels to bring value to investors. Official updates in due course. Don't be tempted and sell cheap. Buy cheap and sell high.

0 · Reply

lev57 Aug. 19 at 4:45 PM

$NRSN I wonder who did it. Maybe the one who warned me? The short-termists came and broke up the company. Together we will prevent it from them.

0 · Reply

IntentionalTrades Aug. 19 at 4:29 PM

$NRSN I warned the would be investors, hopefully nobody lost money.

0 · Reply

lev57 Aug. 19 at 4:27 PM

$NRSN The short-termists came to dismantle the company. Together we will prevent this from them.

0 · Reply

lev57 Aug. 19 at 3:52 PM

$NRSN Something is brewing that hasn't been announced yet. It's worth waiting. Don't sell cheap. You'll regret it.

0 · Reply

Stekli27 Aug. 19 at 3:48 PM

$NRSN why such a volume????

0 · Reply

Stekli27 Aug. 19 at 3:05 PM

$NRSN

0 · Reply

lev57 Aug. 19 at 3:02 PM

$NRSN The prophets of wrath have arrived. Aliyah is not suitable for them. Don't sell cheap. Repent.

0 · Reply

IntentionalTrades Aug. 19 at 2:56 PM

$NRSN Bulls trap in the making. Caveat Emptor

0 · Reply

Jameswilson001 Aug. 18 at 9:52 PM

$NRSN

0 · Reply

Zoofar Aug. 18 at 8:29 PM

$NRSN Dead company. nice research Zero execution. run!

0 · Reply

Holla4adolla1 Aug. 18 at 8:19 PM

$NRSN Short term, it looks bearish. Long term, highly bullish as long as there is minimal dilution.

0 · Reply

Babilon1210 Aug. 18 at 8:02 PM

$NRSN Jesus

0 · Reply

lev57 Aug. 18 at 7:28 PM

$NRSN If the trading software blocks a buy order above 0.51.

0 · Reply

lev57 Aug. 18 at 6:56 PM

$NRSN I've been trying for a few days. He doesn't respond to me. I don't understand his ignoring the situation. As soon as he responds, I'll update. In the meantime, we must prevent the crash that some people are taking advantage of us. Together, we will prevent it.

2 · Reply

Cohensha Aug. 18 at 6:48 PM

$NRSN I fear that stock can’t recover from the massive ATM of the last months. Clearly, letter to investors didn’t bring new hope or something that we didn’t know. Somebody try to connect with Alon?

0 · Reply

lev57 Aug. 18 at 6:38 PM

$NRSN You are scaring investors with your predictions of doom. The company has scientific evidence. They have recovered from the situation.

0 · Reply

tiddyy Aug. 18 at 4:55 PM

$NRSN Reverse Split news imminent, retail can push the vote to No, but they will be in serious risk of delisting, will probably do a major offering before getting delisted to mess up shareholders one last time They didn’t put this vote for fun, they knew this was coming for months, and diluted you at $0.50 even, they will take every penny from you and move on with the trial Read the trail, there are no happy endings here

0 · Reply

Market Cap	16.32M
Revenue (ttm)	0.00
Net Income (ttm)	-11.13M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	0.00%
Debt to Equity Ratio	0.00

Volume	1,354,941
Avg Vol	265,514
Day's Range	N/A - N/A
Shares Out	37.77M
Stochastic %K	1%
Beta	1.62
Analysts	Strong Sell
Price Target	$8.38